Table 2.
Prevalence of EBV-DNA (copies/mL) and EBV-antibodies (U/mL) among different subtypes of MS. EBV-DNA was analyzed by qPCR as described previously. Concentration of plasma anti-EBV, IgG and IgM were measurement in an automated instrument, according to the manufacturer's instructions. Data are representative of three independent experiments.
| Saliva |
Serum |
PBMCs |
CSF |
Anti-IgG |
Anti-IgM |
|
|---|---|---|---|---|---|---|
| P/N (%) [mean ± SD] | ||||||
| MS (n = 78) | ||||||
| 1RRMS (n = 46) | 28/18 (60.86) | 21/25 (45.65) | 37/9 (80.43) | 7/15 (31.81) | 43/3 (93.47) | 7/39 (15.21) |
| CSF (n = 22) | [131 ± 14.27] | [288 ± 46.90] | [160 ± 53.29] | [141 ± 20.81] | [21.37 ± 6.51] | [31.68 ± 4.09] |
| 2SPMS (n = 11) | 9/2 (81.81) | 8/3 (72.72) | 10/1 (90.90) | 4/2 (66.66) | 11/0 (100) | 4/7 (36.36) |
| CSF (n = 6) | [144 ± 28.40] | [307 ± 85.17] | [185 ± 51.25] | [131 ± 10.00] | [24.60 ± 6.38] | [30.47 ± 3.41] |
| 3PPMS (n = 21) | 2/19 (9.52) | 1/20 (4.76) | 6/15 (28.57) | 0/10 (–) | 17/4 (80.95) | 0/21 (–) |
| CSF (n = 10) | [128 ± 7.07] | [168] | [122 ± 7.50] | [–] | [14.62 ± 2.82] | [–] |
| Sig. (2-tailed) | ||||||
| Subtypes(1,2) | NK | NS | NS | NS | NS | NS |
| Subtypes(1,3) |
NS | P < 0.05 | P < 0.01 | – | P < 0.001 | – |
| Subtypes(2,3) | NS | P < 0.001 | P < 0.05 | – | P < 0.001 | – |
PRMCs, peripheral mononuclear cells; CSF, cerebrospinal fluid; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS; P, positive; N, negative; NS, not significant.